HLS Therapeutics, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CA40390B1094
CAD
4.91
0.01 (0.2%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About HLS Therapeutics, Inc. stock-summary
stock-summary
HLS Therapeutics, Inc.
Pharmaceuticals & Biotechnology
HLS Therapeutics Inc is a Canada-based company specialized in the pharmaceutical industry. The Company acquires and distributes commercial stage and branded pharmaceutical drugs for the North American markets. The Company focuses mainly on treatment products for the central nervous system and cardiovascular specialties in Canada. Its product pipeline includes clozaril, for the treatment of schizophrenia disorders; absorica, for treatment of skin disease, such as acne; vascepa, for the treatment of hypertriglyceridemia, and trinomial for cardiovascular risk reduction. Apart from its operation in a number of regions in Canada, such as Toronto, Ontario, and Montreal, the Company also operates in the United States.
Company Coordinates stock-summary
Company Details
10 Carlson Crt Suite 410 , ETOBICOKE ON : M9W 6L2
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 0 Foreign Institutions (0%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
20 Million
(Quarterly Results - Jun 2025)
Net Profit:
-4 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

CAD 178 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.65

stock-summary
Return on Equity

-21.11%

stock-summary
Price to Book

1.96